Wutah dodolan YoY sajrone 12 wulan kepungkur: Novo Nordisk A/S (NVO)

Logo grafis novonordisk.com (NVO)

Scaling plants in Europe and the US supports colossal demand for Wegovy and Ozempic. The year-over-year sales growth percentage for TTM visualizes this expansion, where the value of 11.00 expresses the metric level. Revenue stability is based on the regular consumption of diabetes medications, which guarantees Novo Nordisk A/S (NVO) a predictable financial result and high business resilience.

Wutah pendapatan YoY sajrone 12 wulan kepungkur Novo Nordisk AS (NVO): kanggo periode 11.02.2024 - 19.11.2026

Novo Nordisk - rincian analitis lan metrik utama (NVO)

- rega lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:Novo Nordisk Group - NVO
Produk asil prodhuksi novonordisk.com

This indicator determines the revenue growth rate over a rolling year, excluding seasonal anomalies to provide an objective assessment of business scaling. Analyzing the rolling 12-month sales dynamics versus the same period last year allows for a comparison of financial results with the expansion of Novo Nordisk A/S (NVO) in the diabetes and obesity segments, where synergy from the acquisition of new technological platforms directly converts into accelerated operational growth.